advertisement
Abstract #6841 Published in IGR 4-1
Effect of prostaglandin F2 alpha on proliferation of corneal endothelial cells in vitro
Rieck P; Edelmann B; Schmidt S; Hartmann COphthalmologe 2001; 98: 1157-1161
INTRODUCTION: Prostaglandins, especially PG-F2α, have recently been introduced as a new local glaucoma medication. The modulation of cell proliferation and collagen synthesis in various tissues are the major effects of these agents. However, it is not known whether PG-F2α also modulates proliferation of the corneal endothelium. METHODS: Bovine corneal endothelial cells (BCEC) were cultured according to established protocols. Experiments were performed after the first passage under serum-reduced conditions. A total of 104 cells/well were seeded and the cells were then incubated with different (5 x 10-6 bis 5 x 10-4 mg/ml) concentrations of PG-F2 (Sigma). The number of cells was determined every 24 hours until day 5. Toxicity tests were performed by means of the trypan blue exclusion assay. RESULTS: PG-F2α induced a significant stimulation of BCEC proliferation with all concentrations tested. At the highest concentration of PG-F2α, a two-fold increase in cell number was found after five days only compared to unsupplemented control cultures. No signs of cellular toxicity or morphological alterations could be detected in PG-F2α-supplemented cells. DISCUSSION: For the first time, the present study demonstrates a stimulatory effect of PG-F2α on the corneal endothelium. It appears that this effect is also induced by the PG-F2α concentration determined in the aqueous humour of patients after topical latanoprost application. However, due to the strong contact inhibition of endothelial cells in situ, these results cannot be directly extrapolated to the situation in patients with topical latanoprost treatment.LA: German
Dr. P. Rieck, Universitats-Augenklinik Charite, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. peter.rieck@charite.de
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
